2574 active not recruiting. 2574 Phase 2, 545 Phase 1, 96 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2574 | Active not recruiting 2574 |
| Phase 1 | 545 | Active not recruiting 545 |
| Phase 3 | 96 | Active not recruiting 96 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 140 | 2026-07-01 | 2026-07-17 |
| A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS AS1986NS - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 1 / Phase 2 | Active not recruiting | Antelope Surgical Solutions, Inc | 15 | 2026-07-01 | 2026-10-16 |
| Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations asciminib 200 mg BID - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Thomas Ernst, PD Dr. med. | 50 | 2026-06-22 | 2026-08-27 |
| Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI eparlitozoviril, Control group - HCC - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-06-12 | 2026-06-18 |
| Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer Camrelizumab, Platinum-based Chemotherapy plus PD-1 inhibitor, De-escalated Radiotherapy - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 180 | 2026-06-12 | 2026-08-28 |
| Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Active not recruiting | Harbin Medical University | 96 | 2026-06-10 | 2026-07-02 |
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer Anlotinib + Cadonilimab, PULSAR - Previously Treated, Advanced, Biliary Tract Cancers | Phase 2 | Active not recruiting | West China Hospital | 26 | 2026-06-03 | 2026-06-09 |
| Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies Psychotherapy, Psilocybin, Survey Administration - Anxiety, Depression | Phase 2 | Active not recruiting | University of Washington | 16 | 2026-05-19 | 2026-10-29 |
| PET/CT-Guided Maintenance Therapy in Previously Untreated MZL Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 45 | 2026-05-14 | 2026-11-04 |
| A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Povetacicept, Placebo - Myasthenia Gravis, Generalized | Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 34 | 2026-05-13 | 2026-10-29 |
| Phase 2 Clinical Trial of 177Lu-P17-088 for mAPMR Prostate Cancer 177Lu-P17-088 - Prostate Cancer | Phase 2 | Active not recruiting | First Affiliated Hospital of Fujian Medical University | 25 | 2026-04-29 | 2026-10-27 |
| Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. Sintilimab + Ipilimumab (N01) + AG, Sintilimab Combined with Albumin-bound Paclitaxel and Gemcitabine (AG) - Biliary Tract Cancers (BTC) | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 107 | 2026-04-24 | 2026-06-17 |
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Venetoclax - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Active not recruiting | AbbVie | 14 | 2026-03-17 | 2026-09-09 |
| Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy Camrelizumab + Risedronate Sodium + Chemotherapy - Breast Cancer Triple Negative Breast Cancer | Phase 2 | Active not recruiting | Harbin Medical University | 30 | 2026-03-04 | 2026-03-13 |
| Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors - Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-02-24 | 2026-06-15 |
| Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE) Conversion Surgery, Systemic Therapy/Standard of Care - Gastric Cancer Stage IV, Peritoneal Metastasis | Phase 2 / Phase 3 | Active not recruiting | National University Hospital, Singapore | 300 | 2026-02-21 | 2026-05-14 |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma JNJ-79635322 - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 168 | 2026-02-08 | 2026-11-03 |
| Evaluate RLS-1496 Topical Cream for Actinic Keratosis RLS-1496 1.0% cream - Actinic Keratosis (AK) | Phase 1 / Phase 2 | Active not recruiting | Rubedo Life Sciences, Inc. | 24 | 2026-02-03 | 2026-08-12 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
Showing 20 of 2574. Sign in to see all of them.
Breast Neoplasms (239) · Carcinoma, Non-Small-Cell Lung (229) · Prostatic Neoplasms (146) · Multiple Myeloma (143) · Colorectal Neoplasms (121) · Neoplasm Metastasis (109) · Melanoma (102) · Squamous Cell Carcinoma of Head and Neck (101) · Leukemia, Myeloid, Acute (99) · Lung Neoplasms (93) · Pancreatic Neoplasms (87) · Lymphoma (81) · Ovarian Neoplasms (78) · Recurrence (74)
Neoplasms by Site (1639) · Neoplasms by Histologic Type (1400) · Hemic and Lymphatic Diseases (674) · Neoplasms, Glandular and Epithelial (573) · Immune System Diseases (536) · Immunoproliferative Disorders (525) · Lymphoproliferative Disorders (511) · Hematologic Diseases (439) · Digestive System Diseases (429) · Urogenital Diseases (427) · Digestive System Neoplasms (421) · Carcinoma (419) · Lymphatic Diseases (418) · Urogenital Neoplasms (414)
pembrolizumab (247) · Nivolumab (169) · Specimen Handling (158) · Carboplatin (149) · Cyclophosphamide (147) · Magnetic Resonance Spectroscopy (145) · Cisplatin (126) · Biopsy (119) · Paclitaxel (112) · Radiotherapy (103) · Dexamethasone (98) · Rituximab (87) · Gemcitabine (86) · durvalumab (86) · Doxorubicin (81)
National Cancer Institute (NCI) (219) · M.D. Anderson Cancer Center (192) · Memorial Sloan Kettering Cancer Center (128) · AstraZeneca (43) · Dana-Farber Cancer Institute (42) · City of Hope Medical Center (40) · Sun Yat-sen University (32) · H. Lee Moffitt Cancer Center and Research Institute (27) · Massachusetts General Hospital (25) · St. Jude Children's Research Hospital (25) · Mayo Clinic (23) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (23) · Washington University School of Medicine (20) · Merck Sharp & Dohme LLC (19) · Fudan University (18)
United States (1753) · China (369) · Spain (304) · France (297) · Canada (288) · Italy (236) · United Kingdom (206) · Australia (191) · Germany (178) · South Korea (177) · Netherlands (131) · Belgium (130) · Japan (118) · Taiwan (99) · Poland (92)
Sriram Yennu (7) · Alex F Herrera (5)
PMID 31401903, PMID 41671463, PMID 33357481, PMID 34393061, PMID 35623069, PMID 36648215, PMID 39319495, PMID 40550489, PMID 34515338, PMID 37934000, PMID 40340830, PMID 12473512, PMID 17340590, PMID 26187751, PMID 27324428, PMID 27503501, PMID 28714866, PMID 29567784, PMID 29618479, PMID 30627694, PMID 31838007, PMID 32027845, PMID 33394722, PMID 33604999, PMID 33607632, PMID 33963014, PMID 34182226, PMID 34398557, PMID 34608724, PMID 34797699, PMID 34904813, PMID 35115306, PMID 35285981, PMID 35622074, PMID 37185961, PMID 37328287, PMID 37505794, PMID 38421243, PMID 38421252, PMID 38573872, PMID 38953850, PMID 39563886, PMID 39777725, PMID 40073835, PMID 40073837, PMID 40086048, PMID 40135712, PMID 40179330, PMID 40226119, PMID 40341124
2023 (118), U10CA180820 (56), 2019 (34), P30CA033572 (29), 2017 (27), U10CA180888 (25), UM1CA186689 (24), U10CA180886 (23), 2018 (22), U10CA180821 (22), U24CA196172 (19), 2016 (18), 2015 (17), U10CA180868 (17), UM1CA186709 (15)